Finally, other CXCR4 antagonists are being evaluated in phase I to phase III clinical trials for treatment of renal cell and hepatocellular carcinoma, Waldenstrom’s macroglobulinemia, and breast cancer (Table 4). This evidence concerns the gene CXCR4 and Waldenstrom macroglobulinemia.